Star Equity (STRR) 10-Q 4 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 21, 2014
Document And Entity Information [Abstract]	'	'
Entity Registrant Name	'DIGIRAD CORP	'
Entity Central Index Key	'0000707388	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	18,598,279

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Comprehensive Income (Loss) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:	'	'	'	'
Diagnostic Services	$11,340	$9,475	$20,895	$18,414
Diagnostic Imaging	3,247	3,415	6,689	6,022
Total revenues	14,587	12,890	27,584	24,436
Cost of revenues:	'	'	'	'
Diagnostic Services	8,204	7,179	15,738	14,004
Diagnostic Imaging	1,878	1,918	3,899	3,822
Total cost of revenues	10,082	9,097	19,637	17,826
Gross profit	4,505	3,793	7,947	6,610
Operating expenses:	'	'	'	'
Research and development	0	177	0	996
Marketing and sales	1,245	1,009	2,340	2,245
General and administrative	2,193	2,571	4,188	4,673
Amortization of intangible assets	104	58	170	123
Restructuring charges	138	610	579	1,614
Total operating expenses	3,680	4,425	7,277	9,651
Income (loss) from operations	825	-632	670	-3,041
Interest and other income, net	'	'	'	'
Interest and other income, net	15	16	32	39
Interest expense	-9	-4	-17	-5
Total other income	6	12	15	34
Income (loss) before income taxes	831	-620	685	-3,007
Income tax benefit (expense)	-8	4	-10	-28
Net income (loss)	823	-616	675	-3,035
Net income (loss) per share - basic (in dollars per share)	$0.04	($0.03)	$0.04	($0.16)
Net income (loss) per share - diluted (in dollars per share	$0.04	($0.03)	$0.04	($0.16)
Weighted average shares outstanding – basic	18,554	19,032	18,536	19,177
Weighted average shares outstanding – diluted	18,839	19,032	18,831	19,177
Other comprehensive income (loss):	'	'	'	'
Unrealized gain (loss) on marketable securities	8	-19	-10	-58
Total other comprehensive income (loss)	8	-19	-10	-58
Comprehensive income (loss)	$831	($635)	$665	($3,093)

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'		'
Cash and cash equivalents	$11,579		$18,744
Securities available-for-sale	9,825		7,673
Accounts receivable, net	6,219		5,430
Inventories, net	3,495		3,881
Other current assets	422		697
Restricted cash	477		244
Total current assets	32,017		36,669
Property and equipment, net	4,586		4,153
Intangible assets, net	2,763		353
Goodwill	1,337	[1],[2]	184
Other assets	72		92
Total assets	40,775		41,451
Liabilities and stockholders’ equity	'		'
Accounts payable	1,478		611
Accrued compensation	2,555		3,472
Accrued warranty	155		137
Deferred revenue	1,478		1,631
Other accrued liabilities	1,868		1,774
Total current liabilities	7,534		7,625
Other liabilities	774		440
Total liabilities	8,308		8,065
Commitments and contingencies	'		'
Stockholders’ equity:	'		'
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding	0		0
Common stock, $0.0001 par value: 80,000,000 shares authorized; 18,598,279 and 18,504,279 shares issued and outstanding (net of treasury shares) at June 30, 2014 and December 31, 2013, respectively	2		2
Treasury stock, at cost; 2,588,484 shares at June 30, 2014 and December 31, 2013	-5,728		-5,728
Additional paid-in capital	155,384		156,968
Accumulated other comprehensive loss	-12		-2
Accumulated deficit	-117,179		-117,854
Total stockholders’ equity	32,467		33,386
Total liabilities and stockholders’ equity	$40,775		$41,451
[1]	mortization expense for intangible assets, net was $0.2 million and $0.1 million for the six months ended June 30, 2014 and 2013, respectively. Estimated amortization expense for intangible assets for the remainder of 2014 is $0.2 million, for 2015 is $0.4 million, for 2016 is $0.4 million, for 2017 is $0.4 million, for 2018 is $0.3 million, for 2019 and thereafter is $1.2 million.
[2]	As a result of our acquisition of Telerhythmics on March 13, 2014, we recored certain intangible assets. See Note 3.

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	18,598,279	18,504,279
Common stock, shares outstanding	18,598,279	18,504,279
Treasury stock, shares	2,558,484	2,588,484

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating activities	'	'
Net income (loss)	$675	($3,035)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	774	849
Amortization of intangible assets	170	123
Provision for bad debt	107	46
Stock-based compensation	111	226
Gain on sale of assets and license agreement	-15	0
Amortization of premiums on investments	105	99
Changes in operating assets and liabilities:	'	'
Accounts receivable	-640	-129
Inventories	444	393
Other assets	352	25
Accounts payable	634	270
Accrued compensation	-1,086	172
Deferred revenue	-153	-194
Other liabilities	-146	-409
Restricted cash	-233	0
Net cash provided by (used in) operating activities	1,099	-1,564
Investing activities	'	'
Purchases of property and equipment	-770	-505
Net proceeds from sale of property and equipment	27	0
Purchases of securities available-for-sale	-2,617	-4,679
Sales and maturities of securities available-for-sale	350	2,971
Net cash paid for acquisition	-3,470	0
Net cash used in investing activities	-6,480	-2,213
Financing activities	'	'
Issuances of common stock	158	282
Repurchases of common stock	0	-3,034
Dividend paid	-1,853	0
Repayment of obligations under capital leases	89	37
Net cash used in financing activities	-1,784	-2,789
Net decrease in cash and cash equivalents	-7,165	-6,566
Cash and cash equivalents at beginning of period	18,744	19,514
Cash and cash equivalents at end of period	$11,579	$12,948

The_Company

The Company	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
The Company	'
	The Company
	Digirad Corporation (“Digirad”), a Delaware corporation, is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound imaging services, and also provides cardiac event monitoring services. These services are provided to physician practices, hospitals and imaging centers through our Diagnostic Services reportable segment. Digirad also sells medical diagnostic imaging systems, including solid-state gamma cameras, for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products sold, through our Diagnostic Imaging reportable segment. These two reportable segments, Diagnostic Services and Diagnostic Imaging, are collectively referred to herein as the “Company.”
	The accompanying condensed consolidated financial statements include the operations of both segments. Intercompany accounts and transactions are accounted for at cost and have been eliminated in consolidation. All our long-lived assets are located in the United States and substantially all of our revenues arise from sales activity in the United States.
	Basis of Presentation
	The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at December 31, 2013 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2013, filed with the SEC on Form 10-K on March 20, 2014 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. In addition, certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.
	Preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates.
	The financial results for the three and six months ended June 30, 2014 include the financial results of Telerhythmics, LLC for the period since the acquisition date of March 13, 2014. See Note 3 to the unaudited condensed consolidated financial statements for more information related to the acquisition of Telerhythmics, LLC.

Basic_And_Diluted_Net_Loss_Per

Basic And Diluted Net Loss Per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share, Basic and Diluted [Abstract]	'
Basic and Diluted Net Income (Loss) Per Share	'
	Basic and Diluted Net Income (Loss) Per Share
	For the three and six months ended June 30, 2014 and 2013, basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares and vested restricted stock units outstanding during the period. Diluted net income (loss) per common share is calculated to give effect to all dilutive securities, if applicable, using the treasury stock method.
	The following table sets forth the reconciliation of shares used to compute basic and diluted net income (loss) per share for the periods indicated:
		Three Months Ended June 30,		Six Months Ended June 30,
	(shares in thousands)	2014	2013	2014	2013
	Weighted average shares outstanding - basic	18,554	19,032	18,536	19,177
	Dilutive potential common stock outstanding:
	Stock options	285	—	295	—
	Weighted average shares outstanding - diluted	18,839	19,032	18,831	19,177
	The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net income (loss) per share because their effect was anti-dilutive:
		Three Months Ended June 30,		Six Months Ended June 30,
	(shares in thousands)	2014	2013	2014	2013
	Stock options	102	428	83	383
	Restricted stock units	—	10	—	16
	Total	102	438	83	399

Acquisition_of_Telerhythmics_N

Acquisition of Telerhythmics (Notes)	6 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Acquisition of Telerhythmics, LLC	'
	On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC ("Telerhythmics"), a provider of 24 hour cardiac monitoring services. Telerhythmics and Digirad each have a very similar customer base, yet with only minor overlaps in current customers. We believe this similar customer base will allow us to leverage each company’s strengths to grow sales and also diversify Digirad service offerings.
	We paid to the sellers of the membership interest (the "Sellers") aggregate up front consideration of $3.4 million and assumed approximately $131,000 in debt. In addition, there is an aggregate earn-out opportunity of up to $501,000 from the period March 14, 2014 through December 31, 2016 based on the Telerhythmics business meeting certain earnings before interest, taxes, depreciation and amortization (“EBITDA”) milestones. The Sellers will receive fifty percent (50%) of the EBITDA generated by the Telerhythmics business in excess of the EBITDA milestone amounts, which are as follows:
	•	$415,000 of EBITDA for the period from the closing date through December 31, 2014,
	•	$825,000 of EBITDA for the period from January 1, 2015 through December 31, 2015; and
	•	$825,000 of EBITDA for the period from January 1, 2016 through December 31, 2016.
	At June 30, 2014, we have estimated the fair value of the contingent earn-out opportunity to be $220,000. The earn-out opportunity is estimated based on expected performance of the business over the period from the acquisition date through December 31, 2016, utilizing an income approach. It is reasonably possible that our estimate of the earn-out potential could change in the near term. Any adjustment in the estimated earn-out opportunity until settled will be recorded as a gain or loss to current operations in the period the estimate changes.
	As of June 30, 2014, the preliminary allocation of the purchase price to the assets acquired and liabilities assumed on the acquisition date was as follows (in thousands):
			Allocation of purchase price
	Assets
	Current assets:
	Accounts receivable, net		$	256
	Other current assets		34
	Total current assets		290
	Property and equipment, net		290
	Intangible assets, net		2,580
	Goodwill		1,153
	Total assets		$	4,313
	Accounts payable		$	36
	Accrued compensation		169
	Other accrued liabilities		356
	Current portion of long-term debt		131
	Total current liabilities		692
	Other liabilities		174
	Total liabilities		$	866
	The long-term debt was subsequently paid in full on March 28, 2014.
	The goodwill recognized as part of the transaction primarily represents synergies between Digirad and Telerhythmics that were not separately identified as part of the acquisition valuation process. Telerhythmics activities are considered their own operating segment, which is aggregated into our Diagnostic Services reportable segment (formerly Digirad Imaging Solutions). The resulting goodwill from the acquisition is expected to be deductible for Federal and state tax reporting purposes.
	As of June 30, 2014, we are continuing to obtain and evaluate certain information related to the assets acquired and liabilities assumed. We anticipate closing the measurement period by December 31, 2014.
	The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2013. In deriving the proforma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013.
			Three Months Ended June 30,						Six Months Ended June 30,
	(in thousands)		2014			2013			2014		2013
	Revenues		$	14,587		$	14,455		$	28,739	$	27,414
	Net income (loss)		$	836		$	(564	)	$	862	$	(3,098	)
	Included within our consolidated operating results for the three and six months ended June 30, 2014 are Telerhythmics operations for the period March 14, 2014 through June 30, 2014 as follows:
	(in thousands)	Three Months Ended June 30, 2014			Six Months Ended
					30-Jun-14
	Revenues	$	1,306		$	1,560
	Net loss	$	(62	)	$	(229	)
	Included within the results for Telerhythmics is approximately $155 thousand of transaction costs related to the acquisition. These costs are classified as general and administrative expenses in the condensed consolidated statements of comprehensive loss.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis.
	(in thousands)	June 30,			December 31,
		2014			2013
	Raw materials	$	2,639		$	2,619
	Work-in-process	2,872			3,189
	Finished goods	282			616
		5,793			6,424
	Less reserve for excess and obsolete inventories	(2,298		)	(2,543		)
	Inventories, net	$	3,495		$	3,881

Property_and_Equipment_Notes

Property and Equipment (Notes)	6 Months Ended
	Jun. 30, 2014
Property and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	(in thousands)	June 30,			December 31,
		2014			2013
	Machinery and equipment	$	23,382		$	22,596
	Computer hardware and software	2,663			2,497
	Leasehold improvements	900			861
		26,945			25,954
	Accumulated depreciation	(22,359		)	(21,801		)
	Property and equipment, net	$	4,586		$	4,153

Intangibles_and_Goodwill_Notes

Intangibles and Goodwill (Notes)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangibles and Goodwill	'
			30-Jun-14
	(in thousands)		Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with infinite useful lives:
	Goodwill (2)		Indefinite	$	1,337	$	—		$	1,337
	Intangible assets with finite useful lives:
	Customer relationships (2)		8.1	$	4,850	$	(2,764	)	$	2,086
	Trademarks (2)		8.7	600		(19		)	581
	Patents		4.7	141		(111		)	30
	Covenants not to compete (2)		4.7	70		(4		)	66
	Total intangible assets, net			$	5,661	$	(2,898	)	$	2,763
			31-Dec-13
			Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net
	Intangible assets with infinite useful lives:
	Goodwill		Indefinite	$	184	$	—		$	184
	Intangible assets with finite useful lives:
	Customer relationships		3.5	$	2,940	$	(2,622	)	$	318
	Patents		4.9	141		(106		)	35
	Total intangible assets, net			$	3,081	$	(2,728	)	$	353
	-1	Amortization expense for intangible assets, net was $0.2 million and $0.1 million for the six months ended June 30, 2014 and 2013, respectively. Estimated amortization expense for intangible assets for the remainder of 2014 is $0.2 million, for 2015 is $0.4 million, for 2016 is $0.4 million, for 2017 is $0.4 million, for 2018 is $0.3 million, for 2019 and thereafter is $1.2 million.
	-2	As a result of our acquisition of Telerhythmics on March 13, 2014, we recored certain intangible assets. See Note 3.

Restructuring_Charges_Restruct

Restructuring Charges Restructuring and Related Activities Disclosure (Notes)	6 Months Ended
	Jun. 30, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring Charges	'
	Restructuring Charges
	Facilities restructuring initiative
	On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the "Facilities restructuring initiative"). This action was undertaken as the facility had excess space and capacity given our current operating plan. We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease would have continued through February 29, 2016. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations.
	As a result of the Facilities restructuring initiative, we estimate that we will incur in total approximately $0.7 million to $0.9 million in restructuring charges, which we anticipate to be incurred throughout fiscal year 2014. The estimated charges are comprised of lease termination, moving and other related costs. Through June 30, 2014, we have incurred approximately $0.6 million of charges associated with the Facilities restructuring initiative, consisting primarily of lease termination and moving costs. Restructuring liabilities and associated charges are measured at fair value as incurred.
	The following table includes information regarding our Facilities restructuring initiative:
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at June 30, 2014
	Total Facilities restructuring initiative	$	—	$	550	$	522	$	28
	Accrued Facilities restructuring charges at June 30, 2014 are included in the accounts payable and other accrued liabilities line items in the unaudited condensed consolidated balance sheets. All Facilities restructuring charges for the three and six months ended June 30, 2014 are included in the Diagnostic Imaging segment.
	Diagnostic Imaging restructuring initiative
	On February 28, 2013, we announced a plan to restructure our Diagnostic Imaging business to significantly reduce costs and focus on maximizing cash flow from our Diagnostic Services business (the "Diagnostic Imaging restructuring initiative"). The Diagnostic Imaging restructuring initiative included a reduction in force. In addition, as part of the Diagnostic Imaging restructuring initiative, we entered into an agreement in September 2013 with a third party to outsource the majority of the manufacturing associated with our cameras. As a result of the Diagnostic Imaging restructuring initiative, we incurred a total of $1.8 million in restructuring charges, the majority of which were incurred during fiscal year 2013. Included in the total Diagnostic Imaging restructuring initiative charges are $1.6 million of employee related costs, with the remaining costs consisting of contract termination costs and other related costs. All restructuring efforts associated with this initiative were complete as of June 30, 2014.
	The following table includes information regarding our Diagnostic Imaging restructuring initiative:
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at June 30, 2014
	Total Diagnostic Imaging restructuring initiative	$	489	$	29	$	507	$	11
	All accrued Diagnostic Imaging restructuring charges at June 30, 2014 are included in the accrued compensation line item in the unaudited condensed consolidated balance sheets. All Diagnostic Imaging restructuring charges for the three and six months ended June 30, 2014 are included in the Diagnostic Imaging segment.

Financial_Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Financial Instruments	'
	Financial Instruments
	Assets and Liabilities Measured at Fair Value on a Recurring Basis. The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at June 30, 2014 and December 31, 2013.
		Fair Value as of June 30, 2014
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	9,825			$	—			$	9,825
	Liabilities:
	Acquisition related contingent consideration	$	—			$	—			$	220			$	220
		Fair Value as of December 31, 2013
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	7,673			$	—			$	7,673
	The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. We did not reclassify any investments between levels in the fair value hierarchy during the six months ended June 30, 2014.
	The acquisition related contingent consideration is related to our acquisition of Telerhythmics on March 13, 2014.  We will reassess the fair value of the contingent consideration to be settled in cash related to our acquisition of Telerhythmics on a quarterly basis using the income approach, which is a Level 3 measurement. There was no change to the fair value of the acquisition related contingent consideration during the three months ended June 30, 2014. Significant assumptions used in the measurement include probabilities of achieving the EBITDA milestones.
	Securities Available for Sale
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income (loss). The realized gains and losses on these sales were minimal for the three and six months ended June 30, 2014 and 2013.
	The following table sets forth the composition of securities available-for-sale as of June 30, 2014 and December 31, 2013.
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of June 30, 2014 (in thousands)	Years						Gains				Losses
	Corporate debt securities	3 or less		$	9,837			$	5			$	(17	)		$	9,825
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of December 31, 2013 (in thousands)	Years						Gains				Losses
	Corporate debt securities	3 or less		$	7,675			$	—			$	(2	)		$	7,673

Commitments_and_Contingencies_

Commitments and Contingencies (Notes)	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Leases
	We currently lease facilities and certain automotive equipment under non-cancelable operating leases expiring from July 1, 2014 through March 12, 2021. Rent expense is recognized on a straight-line basis over the initial lease term and those renewal periods that are reasonably assured as determined at lease inception. The difference between rent expense and rent paid is recorded as deferred rent and is included in other liabilities. Rent expense was approximately $0.4 million for the three months ended June 30, 2014 and 2013, and $0.8 million for the six months ended June 30, 2014 and 2013.
	As of June 30, 2014, we financed certain information technology and medical equipment and vehicles under capital leases. These obligations are secured by the specific equipment financed under each lease and will be repaid monthly over the remaining lease terms through March 31, 2018.
	The future minimum lease payments due under both non-cancelable operating leases and capital leases having initial or remaining lease terms in excess of one year as of June 30, 2014 are as follows (in thousands):
		Operating		Capital
		Leases		Leases
	2014	$	561	$	136
	2015	966		276
	2016	753		201
	2017	470		52
	2018	409		5
	2019	408		—
	Thereafter	506		—
	Total minimum lease payments	$	4,073	$	670
	Other matters. In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	As of December 31, 2013, we had unrecognized tax benefits of approximately $1.6 million. Included in the unrecognized tax benefits were $1.3 million of tax benefits that, if recognized, would reduce our annual effective tax rate, subject to the valuation allowance. We do not expect our unrecognized tax benefits to change significantly over the next 12 months.
	We file income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. We are no longer subject to income tax examination by tax authorities for years prior to 2008; however, our net operating loss and research credit carry-forwards arising prior to that year are subject to adjustment. It is our policy to recognize interest expense and penalties related to income tax matters as a component of income tax expense.

Segments

Segments	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segments	'
	Segments
	Our reporting segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment.
		Three Months Ended June 30,					Six Months Ended June 30,
	(in thousands)	2014		2013			2014		2013
	Gross profit by segment:
	Diagnostic Services	$	3,136	$	2,296		$	5,157	$	4,410
	Diagnostic Imaging	1,369		1,497			2,790		2,200
	Condensed consolidated gross profit	$	4,505	$	3,793		$	7,947	$	6,610
	Income (loss) from operations by segment:
	Diagnostic Services	$	441	$	(443	)	$	108	$	(588	)
	Diagnostic Imaging (1)	384		(189		)	562		(2,453		)
	Condensed consolidated income (loss) from operations	$	825	$	(632	)	$	670	$	(3,041	)
	Depreciation and amortization:
	Diagnostic Services	$	431	$	357		$	806	$	747
	Diagnostic Imaging	60		122			138		225
	Condensed consolidated depreciation and amortization	$	491	$	479		$	944	$	972
	(in thousands)	As of June 30, 2014		As of December 31, 2013
	Identifiable assets by segment:
	Diagnostic Services	$	17,186	$	11,874
	Diagnostic Imaging	23,589		29,577
	Condensed Consolidated assets	$	40,775	$	41,451
	(1) Included in the Diagnostic Imaging income from operations for the three and six months ended June 30, 2014, are approximately $0.1 million and $0.6 million of charges, respectively, associated with our Diagnostic Imaging and Facilities restructuring initiatives. Included in the Diagnostic Imaging loss from operations for the three and six months ended June 30, 2013, are approximately $0.6 million and $1.6 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 7).

Subsequent_Event_Notes

Subsequent Event (Notes)	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Event	'
	Subsequent Events
	On August 1, 2014, the Company announced a cash dividend of $0.05 per share payable on August 25, 2014 to shareholders of record on August 12, 2014.

Financial_Instruments_policies

Financial Instruments (policies)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments, Policy	'
	The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers.
Securities Available-for-sale, Policy	'
	Securities Available for Sale
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income (loss).

Schedule_of_Earnings_Per_Share

Schedule of Earnings Per Share, Basic and Diluted (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share, Basic and Diluted [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted	'
	The following table sets forth the reconciliation of shares used to compute basic and diluted net income (loss) per share for the periods indicated:
		Three Months Ended June 30,		Six Months Ended June 30,
	(shares in thousands)	2014	2013	2014	2013
	Weighted average shares outstanding - basic	18,554	19,032	18,536	19,177
	Dilutive potential common stock outstanding:
	Stock options	285	—	295	—
	Weighted average shares outstanding - diluted	18,839	19,032	18,831	19,177
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
	The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net income (loss) per share because their effect was anti-dilutive:
		Three Months Ended June 30,		Six Months Ended June 30,
	(shares in thousands)	2014	2013	2014	2013
	Stock options	102	428	83	383
	Restricted stock units	—	10	—	16
	Total	102	438	83	399

Acquisition_of_Telerhythmics_T

Acquisition of Telerhythmics (Tables)	6 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Schedule of Preliminary Allocation of Purchase Price	'
	As of June 30, 2014, the preliminary allocation of the purchase price to the assets acquired and liabilities assumed on the acquisition date was as follows (in thousands):
			Allocation of purchase price
	Assets
	Current assets:
	Accounts receivable, net		$	256
	Other current assets		34
	Total current assets		290
	Property and equipment, net		290
	Intangible assets, net		2,580
	Goodwill		1,153
	Total assets		$	4,313
	Accounts payable		$	36
	Accrued compensation		169
	Other accrued liabilities		356
	Current portion of long-term debt		131
	Total current liabilities		692
	Other liabilities		174
	Total liabilities		$	866
Schedule of Estimated Proforma Results	'
	The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2013. In deriving the proforma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013.
			Three Months Ended June 30,						Six Months Ended June 30,
	(in thousands)		2014			2013			2014		2013
	Revenues		$	14,587		$	14,455		$	28,739	$	27,414
	Net income (loss)		$	836		$	(564	)	$	862	$	(3,098	)
Consolidated Operating Results of Acquired Entity	'
	Included within our consolidated operating results for the three and six months ended June 30, 2014 are Telerhythmics operations for the period March 14, 2014 through June 30, 2014 as follows:
	(in thousands)	Three Months Ended June 30, 2014			Six Months Ended
					30-Jun-14
	Revenues	$	1,306		$	1,560
	Net loss	$	(62	)	$	(229	)

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis.
	(in thousands)	June 30,			December 31,
		2014			2013
	Raw materials	$	2,639		$	2,619
	Work-in-process	2,872			3,189
	Finished goods	282			616
		5,793			6,424
	Less reserve for excess and obsolete inventories	(2,298		)	(2,543		)
	Inventories, net	$	3,495		$	3,881

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Property and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	(in thousands)	June 30,			December 31,
		2014			2013
	Machinery and equipment	$	23,382		$	22,596
	Computer hardware and software	2,663			2,497
	Leasehold improvements	900			861
		26,945			25,954
	Accumulated depreciation	(22,359		)	(21,801		)
	Property and equipment, net	$	4,586		$	4,153

Intangibles_and_Goodwill_Table

Intangibles and Goodwill (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets and Goodwill	'
		30-Jun-14
	(in thousands)	Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with infinite useful lives:
	Goodwill (2)	Indefinite	$	1,337	$	—		$	1,337
	Intangible assets with finite useful lives:
	Customer relationships (2)	8.1	$	4,850	$	(2,764	)	$	2,086
	Trademarks (2)	8.7	600		(19		)	581
	Patents	4.7	141		(111		)	30
	Covenants not to compete (2)	4.7	70		(4		)	66
	Total intangible assets, net		$	5,661	$	(2,898	)	$	2,763
		31-Dec-13
		Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net
	Intangible assets with infinite useful lives:
	Goodwill	Indefinite	$	184	$	—		$	184
	Intangible assets with finite useful lives:
	Customer relationships	3.5	$	2,940	$	(2,622	)	$	318
	Patents	4.9	141		(106		)	35
	Total intangible assets, net		$	3,081	$	(2,728	)	$	353

Restructuring_Charges_Tables

Restructuring Charges (Tables)	6 Months Ended
	Jun. 30, 2014
Facilities Restructuring Initiative [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring and Related Costs	'
	The following table includes information regarding our Facilities restructuring initiative:
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at June 30, 2014
	Total Facilities restructuring initiative	$	—	$	550	$	522	$	28
Diagnostic Imaging Initiative [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring and Related Costs	'
	The following table includes information regarding our Diagnostic Imaging restructuring initiative:
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at June 30, 2014
	Total Diagnostic Imaging restructuring initiative	$	489	$	29	$	507	$	11

Financial_Instruments_Tables

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	'
	The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at June 30, 2014 and December 31, 2013.
		Fair Value as of June 30, 2014
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	9,825			$	—			$	9,825
	Liabilities:
	Acquisition related contingent consideration	$	—			$	—			$	220			$	220
		Fair Value as of December 31, 2013
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	7,673			$	—			$	7,673
Available-for-sale Securities	'
	The following table sets forth the composition of securities available-for-sale as of June 30, 2014 and December 31, 2013.
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of June 30, 2014 (in thousands)	Years						Gains				Losses
	Corporate debt securities	3 or less		$	9,837			$	5			$	(17	)		$	9,825
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of December 31, 2013 (in thousands)	Years						Gains				Losses
	Corporate debt securities	3 or less		$	7,675			$	—			$	(2	)		$	7,673

Commitments_and_Contingencies_1

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Lease Payments for Capital Leases	'
	The future minimum lease payments due under both non-cancelable operating leases and capital leases having initial or remaining lease terms in excess of one year as of June 30, 2014 are as follows (in thousands):
		Operating		Capital
		Leases		Leases
	2014	$	561	$	136
	2015	966		276
	2016	753		201
	2017	470		52
	2018	409		5
	2019	408		—
	Thereafter	506		—
	Total minimum lease payments	$	4,073	$	670
Schedule of Future Minimum Rental Payments for Operating Leases	'
	The future minimum lease payments due under both non-cancelable operating leases and capital leases having initial or remaining lease terms in excess of one year as of June 30, 2014 are as follows (in thousands):
		Operating		Capital
		Leases		Leases
	2014	$	561	$	136
	2015	966		276
	2016	753		201
	2017	470		52
	2018	409		5
	2019	408		—
	Thereafter	506		—
	Total minimum lease payments	$	4,073	$	670

Segments_Tables

Segments (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment	'
	Our reporting segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment.
		Three Months Ended June 30,					Six Months Ended June 30,
	(in thousands)	2014		2013			2014		2013
	Gross profit by segment:
	Diagnostic Services	$	3,136	$	2,296		$	5,157	$	4,410
	Diagnostic Imaging	1,369		1,497			2,790		2,200
	Condensed consolidated gross profit	$	4,505	$	3,793		$	7,947	$	6,610
	Income (loss) from operations by segment:
	Diagnostic Services	$	441	$	(443	)	$	108	$	(588	)
	Diagnostic Imaging (1)	384		(189		)	562		(2,453		)
	Condensed consolidated income (loss) from operations	$	825	$	(632	)	$	670	$	(3,041	)
	Depreciation and amortization:
	Diagnostic Services	$	431	$	357		$	806	$	747
	Diagnostic Imaging	60		122			138		225
	Condensed consolidated depreciation and amortization	$	491	$	479		$	944	$	972
Reconciliation of Assets from Segment to Consolidated	'
	(in thousands)	As of June 30, 2014		As of December 31, 2013
	Identifiable assets by segment:
	Diagnostic Services	$	17,186	$	11,874
	Diagnostic Imaging	23,589		29,577
	Condensed Consolidated assets	$	40,775	$	41,451
	(1) Included in the Diagnostic Imaging income from operations for the three and six months ended June 30, 2014, are approximately $0.1 million and $0.6 million of charges, respectively, associated with our Diagnostic Imaging and Facilities restructuring initiatives. Included in the Diagnostic Imaging loss from operations for the three and six months ended June 30, 2013, are approximately $0.6 million and $1.6 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 7).

The_Company_Details

The Company (Details)	6 Months Ended
	Jun. 30, 2014
	segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of reportable segments	2

Basic_and_Diluted_Net_Income_p

Basic and Diluted Net Income per Share (Details)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share, Basic and Diluted [Abstract]	'	'	'	'
Weighted average shares outstanding – basic	18,554	19,032	18,536	19,177
Dilutive potential common stock outstanding:	'	'	'	'
Stock options	285	0	295	0
Restricted stock units	0	0	0	0
Weighted average shares outstanding – diluted	18,839	19,032	18,831	19,177
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share	102	438	83	399
Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share	102	428	83	383
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average outstanding securities excluded from computation of diluted net income (loss) per share	0	10	0	16

Acquisition_of_Telerhythmics_D

Acquisition of Telerhythmics (Details) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended
	Mar. 13, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Mar. 13, 2014
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'	'	'
Net loss	'	$823,000	($616,000)	$675,000	($3,035,000)	'
Telerhythmics [Member]	'	'	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'	'	'
Membership interest acquired in business acquisition (percent)	'	'	'	'	'	100.00%
Aggregate upfront consideration paid	3,400,000	'	'	'	'	'
Debt assumed in business acquisition	'	131,000	'	131,000	'	131,000
Aggregate earn-out opportunity	'	'	'	'	'	501,000
Percentage of EBITDA to be received by sellers (percent)	50.00%	'	'	'	'	'
Estimated fair value of contingent earn-out opportunity	'	220,000	'	220,000	'	'
Accounts receivable, net	'	256,000	'	256,000	'	'
Other current assets	'	34,000	'	34,000	'	'
Total current assets	'	290,000	'	290,000	'	'
Property and equipment, net	'	290,000	'	290,000	'	'
Intangible assets, net	'	2,580,000	'	2,580,000	'	'
Goodwill	'	1,153,000	'	1,153,000	'	'
Total assets	'	4,313,000	'	4,313,000	'	'
Accounts payable	'	36,000	'	36,000	'	'
Accrued compensation	'	169,000	'	169,000	'	'
Other accrued liabilities	'	356,000	'	356,000	'	'
Total current liabilities	'	692,000	'	692,000	'	'
Other liabilities	'	174,000	'	174,000	'	'
Total liabilities	'	866,000	'	866,000	'	'
Revenues	'	14,587,000	14,455,000	28,739,000	27,414,000	'
Net income (loss)	'	836,000	-564,000	862,000	-3,098,000	'
Revenues	'	1,306,000	'	1,560,000	'	'
Net loss	'	-62,000	'	-229,000	'	'
Transaction costs included within results for Telerhythmics	'	155,000	'	155,000	'	'
Year one [Member] | Telerhythmics [Member]	'	'	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'	'	'
Aggregate earn-out opportunity	415,000	'	'	'	'	415,000
Year two [Member] | Telerhythmics [Member]	'	'	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'	'	'
Aggregate earn-out opportunity	825,000	'	'	'	'	825,000
Year three [Member] | Telerhythmics [Member]	'	'	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'	'	'
Aggregate earn-out opportunity	$825,000	'	'	'	'	$825,000

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$2,639	$2,619
Work-in-process	2,872	3,189
Finished goods	282	616
Inventory, gross	5,793	6,424
Less reserve for excess and obsolete inventories	-2,298	-2,543
Inventories, net	$3,495	$3,881

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, and equipment, gross	$26,945	$25,954
Accumulated depreciation	-22,359	-21,801
Property and equipment, net	4,586	4,153
Machinery and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, and equipment, gross	23,382	22,596
Computer hardware and software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, and equipment, gross	2,663	2,497
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, and equipment, gross	$900	$861

Intangibles_and_Goodwill_Detai

Intangibles and Goodwill (Details) (USD $)

3 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Customer Relationships [Member]

Customer Relationships [Member]

Trademarks [Member]

Patents [Member]

Patents [Member]

Noncompete Agreements [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Gross

$1,337,000

[1]

'

$1,337,000

[1]

'

$184,000

'

'

'

'

'

'

Goodwill

1,337,000

[1],[2]

'

1,337,000

[1],[2]

'

184,000

'

'

'

'

'

'

Finite-Lived Intangible Asset, Useful Life

'

'

'

'

'

'8 years 1 month 16 days

[1]

'3 years 6 months

'8 years 8 months 15 days

[1]

'4 years 7 months 27 days

'4 years 10 months 24 days

'4 years 8 months 15 days

[1]

Finite-Lived Intangible Assets, Gross

5,661,000

'

5,661,000

'

3,081,000

4,850,000

[1]

2,940,000

600,000

[1]

141,000

141,000

70,000

[1]

Finite-Lived Intangible Assets, Accumulated Amortization

-2,898,000

'

-2,898,000

'

-2,728,000

-2,764,000

[1]

-2,622,000

-19,000

[1]

-111,000

-106,000

-4,000

[1]

Finite-Lived Intangible Assets, Net

2,763,000

[2]

'

2,763,000

[2]

'

353,000

2,086,000

[1],[2]

318,000

581,000

[1],[2]

30,000

[2]

35,000

66,000

[1],[2]

Amortization of intangible assets

104,000

58,000

170,000

123,000

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Amortization Expense, Remainder of 2014

200,000

'

200,000

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Amortization Expense, 2015

400,000

'

400,000

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Amortization Expense, 2016

400,000

'

400,000

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Amortization Expense, 2017

400,000

'

400,000

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Amortization Expense, 2018

300,000

'

300,000

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Amortization Expense, 2019 and thereafter

$1,200,000

'

$1,200,000

'

'

'

'

'

'

'

'

[1]

As a result of our acquisition of Telerhythmics on March 13, 2014, we recored certain intangible assets. See Note 3.

[2]

mortization expense for intangible assets, net was $0.2 million and $0.1 million for the six months ended June 30, 2014 and 2013, respectively. Estimated amortization expense for intangible assets for the remainder of 2014 is $0.2 million, for 2015 is $0.4 million, for 2016 is $0.4 million, for 2017 is $0.4 million, for 2018 is $0.3 million, for 2019 and thereafter is $1.2 million.

Restructuring_Charges_Faciliti

Restructuring Charges - Facilities Restructuring Initiative (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jan. 27, 2014	Jan. 23, 2014	Jun. 30, 2014	Jun. 30, 2014
					Facilities Restructuring Initiative [Member]	Facilities Restructuring Initiative [Member]	Facilities Restructuring Initiative [Member]	Minimum [Member]	Maximum [Member]
						sqft	sqft	Facilities Restructuring Initiative [Member]	Facilities Restructuring Initiative [Member]
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'	'
Area of Real Estate Property	'	'	'	'	'	47,000	21,300	'	'
Estimated restructuring costs	'	'	'	'	'	'	'	$700,000	$900,000
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'	'	'	'
Restructuring Reserve	'	'	'	'	0	'	'	'	'
Cash payments and other reductions	'	'	'	'	522,000	'	'	'	'
Restructuring Reserve	'	'	'	'	28,000	'	'	'	'
Restructuring Charges	$138,000	$610,000	$579,000	$1,614,000	$550,000	'	'	'	'

Restructuring_Charges_Diagnost

Restructuring Charges - Diagnostic Imaging Restructuring Initiative (Details) (Diagnostic Imaging Initiative [Member], USD $)	6 Months Ended
	Jun. 30, 2014
Restructuring Cost and Reserve [Line Items]	'
Restructuring charges incurred	$1,800,000
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve	489,000
Accrued costs	29,000
Cash payments and other reductions	507,000
Restructuring Reserve	11,000
Employee Severance [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Restructuring charges incurred	$1,600,000

Financial_Instruments_Assets_a

Financial Instruments Assets and Liabilities at Fair Value on a Recurring Basis (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Liabilities, Fair Value Disclosure	$0	'
Level 1 [Member] | Corporate Debt Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Corporate debt securities	0	0
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Liabilities, Fair Value Disclosure	0	'
Level 2 [Member] | Corporate Debt Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Corporate debt securities	9,825	7,673
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Liabilities, Fair Value Disclosure	220	'
Level 3 [Member] | Corporate Debt Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Corporate debt securities	0	0
Total [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Liabilities, Fair Value Disclosure	220	'
Total [Member] | Corporate Debt Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Corporate debt securities	$9,825	$7,673

Financial_Instruments_Securiti

Financial Instruments Securities Available for Sale (Details) (3 years or less [Member], Corporate Debt Securities [Member], USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
3 years or less [Member] | Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Securities maturity period	'3 years	'3 years
Amortized Cost	$9,837	$7,675
Unrealized Gains	5	0
Unrealized Losses	-17	-2
Fair Value	$9,825	$7,673

Commitments_and_Contingencies_2

Commitments and Contingencies (Details) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'	'
Rent expense	$400,000	$800,000	$800,000
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'	'	'
Operating Leases - 2014	561,000	561,000	'
Operating Leases - 2015	966,000	966,000	'
Operating Leases - 2016	753,000	753,000	'
Operating Leases - 2017	470,000	470,000	'
Operating Leases - 2018	409,000	409,000	'
Operating Leases - 2019	408,000	408,000	'
Operating Leases - Thereafter	506,000	506,000	'
Operating Leases - Total minimum lease payments	4,073,000	4,073,000	'
Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'	'	'
Capital Leases - 2014	136,000	136,000	'
Capital Leases - 2015	276,000	276,000	'
Capital Leases - 2016	201,000	201,000	'
Capital Leases - 2017	52,000	52,000	'
Capital Leases - 2018	5,000	5,000	'
Capital Leases - 2019	0	0	'
Capital Leases - Thereafter	0	0	'
Capital Leases - Total minimum lease payments	$670,000	$670,000	'

Income_Tax_Details

Income Tax (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]	'
Unrecognized tax benefits	$1.60
Unrecognized tax benefits that would impact effective tax rate	$1.30

Segments_Details

Segments (Details) (USD $)	3 Months Ended				6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Segment Reporting Information [Line Items]	'		'		'		'
Gross profit by segment	$4,505		$3,793		$7,947		$6,610
Income (loss) from operations by segment	825		-632		670		-3,041
Depreciation and amortization	491		479		944		972
Restructuring charges	138		610		579		1,614
Diagnostic Services [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Gross profit by segment	3,136		2,296		5,157		4,410
Income (loss) from operations by segment	441		-443		108		-588
Depreciation and amortization	431		357		806		747
Diagnostic Imaging [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Gross profit by segment	1,369		1,497		2,790		2,200
Income (loss) from operations by segment	384	[1]	-189	[1]	562	[1]	-2,453	[1]
Depreciation and amortization	60		122		138		225
Facilities Restructuring Initiative [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Restructuring charges	'		'		$550		'
[1]	Included in the Diagnostic Imaging income from operations for the three and six months ended June 30, 2014, are approximately $0.1 million and $0.6 million of charges, respectively, associated with our Diagnostic Imaging and Facilities restructuring initiatives. Included in the Diagnostic Imaging loss from operations for the three and six months ended June 30, 2013, are approximately $0.6 million and $1.6 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 7).

Segments_Asset_by_Segment_Deta

Segments Asset by Segment Detail (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Segment Reporting Information [Line Items]	'	'
Identifiable assets by segment	$40,775	$41,451
Diagnostic Services [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Identifiable assets by segment	17,186	11,874
Diagnostic Imaging [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Identifiable assets by segment	$23,589	$29,577

Subsequent_Event_Detail_Detail

Subsequent Event Detail (Details) (USD $)	3 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Common stock dividends declared (in US$ per share)	$0.05